Iovance Cell Therapy Center (iCTC)

Iovance is building iCTC to become a state-of-the-art cell therapy manufacturing facility in Philadelphia, PA

VIEW MORE

IOVANCE is working to cure cancer, developing transformative immuno-oncology TIL therapies harnessing a patient's immune system.

DISCOVER

TIL (Tumor Infiltrating Lymphocytes) technology is an ideal cancer therapy targeting heterogeneous solid tumors.

EXPLORE

TIL's unique qualities include single treatment, no maintenance or follow-up therapy, and broad-spectrum antigen specificity ideally suited for many solid tumor cancers.

LEARN
ADVANCING IMMUNO-ONCOLOGY

IOVANCE Biotherapeutics is focused on improving patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers.


CLINICAL TRIALS– Now Recruiting

IOVANCE is recruiting patients in four Phase 2 clinical trials to assess the efficacy and safety of autologous cell therapies for treatment of patients with cancer.

C-145-04 is a multicenter clinical trial in patients with metastatic cervical cancer at various sites in the U.S. and Europe.

IOV-LUN-202 is a Phase 2 multicenter clinical trial in patients with metastatic non-small cell lung cancer (NSCLC).

IOV-COM-202 is a multicenter clinical trial in patients with non-small cell lung cancer (NSCLC), metastatic melanoma, and head and neck squamous cell carcinoma (HNSCC) at various sites in the U.S., Canada and Europe.

IOV-CLL-01 is a clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).

Learn
Latest News
May 5, 2022Iovance Biotherapeutics Reports First Quarter 2022 Financial Results and Corporate Updates

First Biologics License Application (BLA) Submission Planned in August 2022 SAN CARLOS, Calif. , May 05, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology comp...

Apr 27, 2022Iovance Biotherapeutics to Present Translational Data for Lifileucel in Advanced Melanoma at 2022 ASCO Annual Meeting

SAN CARLOS, Calif. , April 27, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced ...

Apr 26, 2022Iovance Biotherapeutics to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 5, 2022

SAN CARLOS, Calif. , April 26, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its ...

All News